News & Updates

COVID-19 infection in early pregnancy ups risk of stillbirth
COVID-19 infection in early pregnancy ups risk of stillbirth
08 Mar 2023

Pregnant women who contract COVID-19 during early and mid-pregnancy are at risk of stillbirth, but this risk may not be present when infection occurs at any time during the third trimester or before delivery, as reported in a study.

COVID-19 infection in early pregnancy ups risk of stillbirth
08 Mar 2023
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
08 Mar 2023 byStephen Padilla

Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.

Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
08 Mar 2023
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
08 Mar 2023 byJairia Dela Cruz

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
08 Mar 2023
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
08 Mar 2023
Longer time in BP target protects against adverse cardiovascular events in diabetes
Longer time in BP target protects against adverse cardiovascular events in diabetes
08 Mar 2023

For patients with hypertension and diabetes, longer time spent in blood pressure (BP) target range helps lower the risk of cardiovascular disease, according to a study.

Longer time in BP target protects against adverse cardiovascular events in diabetes
08 Mar 2023
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023 byNatalia Reoutova

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023